Oct 26, 2017
MabVax Therapeutics to Present Three Posters at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Oct 17, 2017
MabVax Therapeutics Holdings, Inc. Provides Corporate Overview and Business Outlook
Oct 11, 2017
MabVax Therapeutics Initiates Patient Enrollment in a Phase 1 Trial for MVT-1075, a New Radioimmunotherapy Treatment for Advanced Pancreatic, Colon and Lung Cancers
Oct 06, 2017
MabVax Stockholders Approve Remaining Proposal at Special Meeting of Stockholders
Sep 22, 2017
MabVax Therapeutics Holdings, Inc. Announces $1.25 Million Registered Direct Offering
Sep 13, 2017
MabVax Therapeutics' HuMab-5B1 Antibody to be Featured in Presentations at the 2017 World Molecular Imaging Congress
Sep 12, 2017
MabVax Therapeutics Holdings, Inc. Announces $2.0 Million Registered Direct Offering
Sep 07, 2017
MabVax Therapeutics Holdings, Inc. to Present at the 19th Annual Rodman & Renshaw Global Investment Conference in New York City
Sep 06, 2017
MabVax Therapeutics Engages Greenhill & Co. as Advisor for Exploring Strategic Alternatives
Aug 22, 2017
MabVax Therapeutics Holdings, Inc. Announces the Closing of $1.3 Million Registered Direct Offering and is Engaging an Advisory Bank to Explore Strategic Alternatives
Jul 24, 2017
MabVax Therapeutics Board of Directors Authorizes the Company to Explore Strategic Alternatives
Jun 27, 2017
MabVax Therapeutics Commences Patient Dosing in MVT-1075 Radioimmunotherapy Phase 1 Clinical Trial for the Treatment of Pancreatic, Colon and Lung Cancers
Jun 05, 2017
MabVax Therapeutics Phase I Trial Results of Antibody Therapy MVT-5873 for the Treatment of Advanced Pancreatic Cancer Presented at the 2017 ASCO Annual Meeting